In 2010, we became the first pharmaceutical company in Australia to disclose how much we pay healthcare professionals for services such as consulting, speaking at meetings and attendance at academic congresses. This disclosure was an annual aggregate figure and did not include payments made to publicly and privately funded groups for conducting research and development or clinical trial projects. Use the links to the left of this page to view aggregate transparency disclosures from 2010 to 2015.
Since 2016 we have published Transfer of Value reports which list all payments to individual healthcare professionals in Australia for the provision of services including:
- payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant.
- airfares, accommodation and/or conference registration fees to attend medical education as part of those services, such as speaking at events or attending advisory boards.
From 30 August 2019, this information will now be held in a database, administered by Medicines Australia. This database is designed to be searchable and the information can also be downloaded as a CSV file.
For further information about the details in the report, or to search the database, please visit Disclosure Australia.
Please note: The Medicines Australia Code transparency of interactions reporting requirements only apply to Medicines Australia Member Companies. Medicines Australia does not routinely report on payments or transfers of value made to Australian HCPs by companies operating in another country or by overseas affiliates. GSK is committed to transparency of all relevant payments made to Australian HCPs including payments made by our GSK affiliates overseas, and we continue to make this information available on request.